Fate Therapeutics (FATE) Misses Q1 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.34), $0.01 worse than the analyst estimate of ($0.33).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Brinker Int'l (EAT) PT Raised to $285 at UBS Following 'Impressive' Q4 Outperformance
• SuperCom (SPCB) Tops Q3 EPS by 43c